Mackenzie Financial Corp Purchases 31,596 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Key Points

• Mackenzie Financial Corp increased its stake in BioCryst Pharmaceuticals by 37.3% in the first quarter, bringing its total to approximately 116,258 shares worth $872,000.
• BioCryst Pharmaceuticals reported earnings of $0.15 per share for the last quarter, significantly exceeding analyst expectations of $0.03, alongside a revenue rise of 49.5% year-over-year.
• Analysts have varying views on BCRX, with a majority rating it as a buy and setting an average target price of $16.70, reflecting optimism about the company's future performance.

Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 37.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,258 shares of the biotechnology company's stock after purchasing an additional 31,596 shares during the quarter. Mackenzie Financial Corp owned approximately 0.06% of BioCryst Pharmaceuticals worth $872,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $125,000. Y Intercept Hong Kong Ltd increased its position in BioCryst Pharmaceuticals by 106.7% during the first quarter. Y Intercept Hong Kong Ltd now owns 141,865 shares of the biotechnology company's stock worth $1,064,000 after acquiring an additional 73,242 shares during the period. Allianz Asset Management GmbH increased its position in BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock worth $103,000 after acquiring an additional 1,200 shares during the period. Hussman Strategic Advisors Inc. bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $2,362,000. Finally, CWM LLC increased its position in BioCryst Pharmaceuticals by 167.5% during the first quarter. CWM LLC now owns 53,750 shares of the biotechnology company's stock worth $403,000 after acquiring an additional 33,656 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 0.6%

BCRX traded down $0.05 during trading on Friday, reaching $8.30. 1,823,000 shares of the company's stock were exchanged, compared to its average volume of 3,745,884. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The stock has a market capitalization of $1.74 billion, a PE ratio of -46.11, a price-to-earnings-growth ratio of 1.90 and a beta of 1.10. The firm has a fifty day moving average price of $9.32 and a two-hundred day moving average price of $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. During the same period in the previous year, the firm earned ($0.06) earnings per share. The company's revenue was up 49.5% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BCRX shares. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Wedbush raised their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.